(Total Views: 237)
Posted On: 05/28/2017 1:48:02 PM
Post# of 72446
SLC responding to loanranger again:
Quote:
slcimmuno Member Level Sunday, 05/28/17 12:26:43 PM
Re: loanranger post# 183479
Post # of 183489
Here's the cite re competing trials
https://www.google.com/amp/s/seekingalpha.com...eo-ehrlich
"At certain sites there are studies competing for these patients. Decisions are being made at CTIX to possibly change certain sites."
We can parse this issue some more ad infinitum (and it's a rather common one... enrollment delays... maybe exclusion criteria were too strict) but isn't this losing sight of the forest for a single tree?
The Interim data was outstanding -- 70% in the placebo arm got Severe OM vs 22% receiving Brilacidin -- suggesting potentially the first Preventative OM. Hundreds of thousands of patients possibly benefiting from this...
Fast Track for OM was first and possibly Breakthrough designation next. I wouldn't be surprised if the trial is stopped early for efficacy if they do another interim. And that doesn't occur all that often at all.
"Why Clinical Trials Are Terminated"
http://biorxiv.org/content/biorxiv/early/2015...3.full.pdf
Lots to be exited about re B -- OM and IBD.
(1)
(0)
